AN EVALUATION OF BONE-DENSITY AND TURNOVER IN PREMENOPAUSAL WOMEN WITH TYPE-1 DIABETES-MELLITUS

被引：59

作者：

GALLACHER, SJ

FENNER, JAK

FISHER, BM

QUIN, JD

FRASER, WD

LOGUE, FC

COWAN, RA

BOYLE, IT

MACCUISH, AC

机构：

[1] Diabetic Unit, Royal Liverpool Hospital, Liverpool

[2] University Department of Medicine, Royal Liverpool Hospital, Liverpool

[3] Institute of Biochemistry, Glasgow Royal Infirmary, Royal Liverpool Hospital, Liverpool

[4] University Department of Clinical Chemistry, Royal Liverpool Hospital, Liverpool

来源：

DIABETIC MEDICINE | 1993年 / 10卷 / 02期

关键词：

OSTEOPOROSIS; DIABETES-MELLITUS; BONE DENSITOMETRY; BONE TURNOVER;

D O I：

10.1111/j.1464-5491.1993.tb00029.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Measurement of bone density and turnover was assessed in 20 premenopausal females with Type 1 diabetes mellitus and 27 age-sex-matched controls. Measurement was made of spinal (L2-4) and neck of femur bone density by dual-energy X-ray absorptiometry. L2-4 density was significantly higher in the diabetic patients compared with controls (1.224 +/- 0.021 g cm-2 vs 1.161 +/- 0.020 g cm-2: p = 0.016). No significant difference was noted between the groups in neck of femur density. Measurement of bone formation was assessed by serum alkaline phosphatase and bone resorption by fasting urinary hydroxyproline/creatinine ratio. Alkaline phosphatase was significantly higher in the diabetic patients (185 +/- 16 Ul-1 vs 135 +/- 10 Ul-1: p < 0.01) as was hydroxyproline/creatinine ratio (0.028 +/- 0.003 vs 0.017 +/- 0.002: p = 0.002). No significant correlation was found between L2-4 density and glycated haemoglobin, duration of diabetes or daily dose of insulin taken. These data suggest that osteopenia is not associated with Type 1 diabetes mellitus; however these patients do have evidence of increased bone turnover and may therefore be at risk of osteoporosis in later life, particularly after the menopause.

引用

页码：129 / 133

页数：5

共 28 条

[1] Albright F., Reifenstein EC, The Parathyroid Glands and Metabolic Bone Disease: Selected Studies, (1948)
[2] Levein ME, Boisseau VC, Avioli LV, Effects of diabetes mellitus on bone mass in juvenile and adult onset diabetes, New England Journal of Medicine, 294, pp. 241-245, (1976)
[3] Rosenbloom AL, Lezotte DC, Weber FT, Gudat J., Heller DR, Weber ML, Et al., Diminution of bone mass in childhood diabetes, Diabetes, 26, pp. 1052-1055, (1977)
[4] Auwerx J., Dequeker J., Bouillon R., Geusens P., Nijs J., Mineral metabolism and bone mass at peripheral and axial skeleton in diabetes mellitus, Diabetes, 37, pp. 8-12, (1988)
[5] Paganini-Hill AL, Ross RK, Gerkins VR, Henderson BE, Arthur M., Mack TM, Menstrual estrogen therapy and hip fractures, Annals of Internal Medicine, 95, pp. 28-31, (1981)
[6] Heath H., Melton LJ, Chu-Pin C., Diabetes mellitus and the risk of skeletal fracture, N Engl J Med, 303, pp. 567-570, (1980)
[7] Gallacher SJ, Fenner JAK, Anderson K., Bryden FM, Banham SW, Logue FC, Et al., Intravenous pamidronate in the treatment of corticosteroid dependent lung disease—an open, pilot study, Thorax, 47, pp. 932-936, (1992)
[8] Gardner MD, Dryburgh FJ, Fyffe JA, Jenkins AS, Predictive value of derived calcium figures based on the measurement of ionised calcium, Ann Clin Biochem, 18, pp. 106-109, (1981)
[9] Logue FC, Perry B., Chapman RS, Milne I., James K., Beastall GH, A two‐site immunoradiometric assay for PTH (1–84) using N and C terminal specific monoclonal antibodies, Ann Clin Biochem, 28, pp. 160-166, (1991)
[10] Reinhardt TA, Horst RL, Orf JW, Hollis BW, A microassay for 1,25‐dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies, J Clin Endocrinol Metab, 58, pp. 91-98, (1984)

← 1 2 3 →